REG - Oxford Biomedica PLC - Block listing Application

Oxford BioMedicaAnnouncement

01/04/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA9539Ga&default-theme=true

RNS Number : 9539G  Oxford Biomedica PLC  01 April 2022

 

 

 

Oxford Biomedica

Block listing Application

 

Oxford, UK - 01 April 2022: Oxford Biomedica plc ("Oxford Biomedica" or the
"Company") (LSE:OXB), a leading gene and cell therapy Group announces that
applications have been made to the Financial Conduct Authority and the London
Stock Exchange for admission to (i) the Premium segment of the Official List
and (ii) to trading on the London Stock Exchange for a block listing of
500,000 ordinary shares of 50 pence each (the "Ordinary Shares").

 

The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes:

 

·      OXB Long Term Incentive Plan (LTIP) (300,000 Ordinary Shares);
and

·      OXB Employee Share Option Scheme (ESOS) (200,000 Ordinary
Shares).

 

It is expected that admission of the Ordinary Shares will become effective on
06 April 2022. The Ordinary Shares will rank pari passu in all respects with
the Group's existing ordinary shares in issue.

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group. In January 2022, Oxford Biomedica announced that it was
broadening its leading viral vector offerings by incorporating Homology
Medicines' established AAV capabilities into a newly formed AAV Manufacturing
and Innovation Business in the US with Homology Medicines as a 20% owner. To
date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector
leading lentiviral vector delivery platform (LentiVector®), which the Group
leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam
Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSKFLBBLZLXBBL